Retinal Pharmacotherapy

Quan Nguyen, MD. MSc, Associate Professor of Ophthalmology, Diseases of the Retina and Vitreous, and Uveitis, Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA
Eduardo Rodrigues, MD, Department of Ophthalmology, Vision Institute, Federal University of São Paulo, São Paulo, Brazil
Michel Farah, MD, Professor of Ophthalmology and Vice-chairman, Retina and Vitreous Department, Vision Institute Federal University of São Paulo, São Paulo, Brazil
William Mieler, MD, Professor and Vice-Chairman, Department of Ophthalmology & Visual Sciences, University of Illinois at Chicago, IL, USA

Retinal Pharmacotherapy is the first comprehensive book devoted to pharmacologic agents and their rationale and mechanisms of action in selected retinal and uveitic diseases. Drs. Quan Dong Nguyen, Eduardo Buchele Rodrigues, Michel Eid Farah, and William F. Mieler lead an international team of expert contributors to present up-to-date knowledge of new drugs on the market, the science behind the drugs, evidence of how the drugs work, and the reasons why they are effective or not. This user-friendly, all-in-one reference provides you with easy access to practical information on the effective and appropriate use of pharmacologic agents in the management of retinal diseases.

Audience
Opthalmology, Optometrist

Buy this

Hardbound, 408 Pages

Published: February 2010

Imprint: Saunders

ISBN: 978-1-4377-0603-1

1 Evolving Knowledge in Pharmacologic
Treatments
Section 1: Basic Sciences in Retina
2 Retinal Anatomy and Pathology
3 Retinal Biochemistry, Physiology and
Cell Biology
4 Ocular Angiogenesis: Vascular Endothelial
Growth Factor and Other Factors
5 Ocular Immunity and Inflammation
6 Complement Activation and Inhibition in
Retinal Disease
7 Genetics of Retinal Disease
Section 2: Animal Models and Routes for
Retinal Drug Delivery
8 Vitamins and Supplements for Age-Related
Macular Degeneration
9 Ocular Pharmacokinetic, Drug Bioavailability and Intraocular Drug Delivery Systems
0 Routes for Drug Delivery to the Eye and Retina: Intravitreal Injections and Vitrectomy
11 Routes for Drug Delivery: Topical, Transscleral, Suprachoroidal, and Intravitreal
Gas-Phase Nanoparticles
12 Routes for Drug Delivery: Sustained-Release
Devices
13 Microspheres and Nanotechnology for
Drug Delivery
14 Thermo-sensitive Hydrogels
15 Retina and Ocular Toxicity to Ocular Application
of Drugs
16 Retinal Toxicity of Systemic and Topical
Medications
Section 3: Retinal Diseases Amenable to Pharmacotherapy
17 Non-neovascular Age-Related Macular
Degeneration
18 Neovascular Age-Related Macular Degeneration
19 Diabetic Retinopathy and Diabetic
Macular Edema
20 Retinal Vein Occlusion
21 Retinal Detachment and Proliferative
Vitreoretinopathy
22 Posterior Uveitis
23 Choroidal Neovascularization Secondary
to Inflammation, Infection, and Myopia
24 Ocular Infection: Endophthalmitis
25 Retinopathy of Prematurity
26 Idiopathic Macular Telangiectasia
27 Neovascular Glaucoma
28 Retinal Hereditary and Degenerative /
Dystrophic Diseases (non-AMD)
Section 4: Drugs and Mechanisms in
Retinal Diseases
29 Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
in the Treatment of Retinal Diseases
30 Corticosteroids: Triamcinolone, Dexamethasone, Fluocinolone, and Others
31 Anecortave Acetate
32 Therapeutic Monoclonal Antibodies and
Fragments: Bevacizumab
33 Therapeutic Monoclonal Antibodies and
Fragments: Ranibizumab
34 Pathophysiology of Vascular Endothelial Growth
Factor and Other Angiogenic Molecules
35 Biologic Therapies: Infliximab, Adalimumab,
Etanercept, Daclizumab, and Others
36 Immunomodulatory Therapy in Uveitis
37 Fusion Proteins: VEGF-Trap
38 Aptamers and Intramers: Pegaptanib
39 Protein Kinase C Inhibitor: Ruboxistaurin
40 Small-Interference RNA Technology: SIRNA 027, Bevasiranib, and REDD14NP
41 Ocular Gene Therapy
42 Neuroprotection and Retinal Diseases
43 Photosensitizers and Photodynamic Therapy:
Verteporfin
44 Chemotherapy for Malignant Intraocular Tumors
45 Antibiotics
Section 5: Pharmacotherapy and Surgery
46 Rheotherapy (Rheopheresis; Therapeutical
Apheresis)
47 Enzymatic Vitrectomy and Pharmacologic
Vitreodynamics
48 The Use of Vital Dyes during Vitreoretinal Surgery - Chromovitrectomy
49 Epimacular and External Radiotherapy
50 Current Status of Human Retinal Pigment
Epithelial Transplantation
Section 6: The Last Words
51 Off-Label Drugs and the Impact of the Food and
Drug Administration in the Treatment of
Retinal Disease
52 Value-Based Medicine and Pharmacoeconomics
53 Future Perspectives: Agents on the Horizon

Retinal Pharmacotherapy

Contents